Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674358 | 0.90 | SMPD1 (0.56) | MAPK1KMT2AHTR1AKDM4ELMNA | |
| SCHEMBL5052312 | 0.90 | NPC1 (0.57) | MAPTKMT2AHTR1AKDM4ELMNA | |
| SCHEMBL8982918 | 0.85 | RAB9A (0.57) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL28116529 | 0.84 | MAPT (0.53) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL6582124 | 0.84 | NPC1 (0.56) | MAPTMAPK1TDP1L3MBTL1KMT2A | |
| SCHEMBL27613678 | 0.84 | S1PR5 (0.48) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL1615947 | 0.84 | FFAR4 (0.56) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL8982724 | 0.84 | RAB9A (0.46) | MAPTMAPK1TDP1L3MBTL1KMT2A | |
| SCHEMBL2094089 | 0.81 | MAPT (0.48) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL27594898 | 0.80 | MRGPRX4 (0.50) | MAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | claimed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | claimed |
| WO-2010136804-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTIBIOTICS | ASTON UNIVERSITY (GB) | 2010-12-02 | — | — | WO | claimed |
| JP-8208687-A | — | — | None | — | — | JP | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20210299253-A1 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME | PROTECH CO., LTD. (KR) | 2021-09-30 | — | — | US | disclosed |
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | disclosed |
| EP-2653465-B1 | Opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-13 | — | — | EP | disclosed |
| EP-2573068-B9 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2573068-B1 | Process for preparing intermediates of compounds useful as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-31 | — | — | EP | disclosed |
| EP-1175385-A1 | D-MANNITOL DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Pharmacor Inc. (CA) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066524-A1 | D-MANNITOL DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PHARMACOR INC. (CA) | 2000-11-09 | — | — | WO | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| JP-H08208687-A | GLYCERYL OLIGONUCLEOTIDE | SANKYO CO LTD | 1996-08-13 | — | — | JP | disclosed |
| US-4500452-A | NOT SUBJECT TO ENZYME DEACTIVATION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-02-19 | — | — | US | disclosed |
| US-4472304-A | CARCINOSTATIC | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4280008-A | CHEMICAL INTERMEDIATES FOR OPTICALLY ACTIVE AMINO ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | MAPT 288/4885MAPK1 2235/4885TDP1 3803/4885 |
| US-20210299253-A1 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME | ATG7, SQSTM1, CTSA | MAPT 24/4885MAPK1 2969/4885TDP1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.